MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$5,838,000
EPS
-$0.19
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenue
0 0 0 0
Research and development
3,073,000 2,002,000 1,681,000 4,292,000
General and administrative
2,157,000 1,957,000 3,811,000 2,579,000
Impairment loss on intangible assets
-28,700,000 --
Total operating expenses
5,230,000 32,659,000 5,492,000 6,871,000
Loss from operations
-5,230,000 -32,659,000 -5,492,000 -6,871,000
Other (expense) income, net
-608,000 -20,000 -89,000 49,000
Income tax benefit
--712,000 --
Net loss
-5,838,000 -31,967,000 -5,581,000 -6,822,000
Unrealized gain on investments, net of tax of 0
0 18,000 0 12,000
Foreign currency translation adjustments
0 -36,000 0 -24,000
Total other comprehensive loss
0 -18,000 0 -12,000
Total comprehensive loss
-5,838,000 -31,985,000 -5,581,000 -6,834,000
Basic EPS
-0.19 -1.091 -0.21 -0.28
Diluted EPS
-0.19 -1.091 -0.21 -0.28
Basic Average Shares
30,354,647 29,314,367 26,361,386 24,187,536
Diluted Average Shares
30,354,647 29,314,367 26,361,386 24,187,536
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Total comprehensiveloss-$5,838,000 (-5.86%↓ Y/Y)Net loss-$5,838,000 (-6.13%↓ Y/Y)Loss from operations-$5,230,000 (6.76%↑ Y/Y)Other (expense)income, net-$608,000 (-662.96%↓ Y/Y)Total operatingexpenses$5,230,000 (-6.76%↓ Y/Y)Research and development$3,073,000 (0.62%↑ Y/Y)General andadministrative$2,157,000 (-15.58%↓ Y/Y)

Rein Therapeutics, Inc. (RNTX)

Rein Therapeutics, Inc. (RNTX)